Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 3
1990 2
1991 1
1992 3
1993 3
1994 1
1995 2
1997 4
1998 6
1999 13
2000 28
2001 31
2002 37
2003 43
2004 67
2005 72
2006 76
2007 83
2008 94
2009 59
2010 71
2011 90
2012 94
2013 113
2014 102
2015 109
2016 105
2017 108
2018 91
2019 88
2020 98
2021 84
2022 66
2023 69
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

1,736 results

Results by year

Filters applied: . Clear all
Page 1
Exemestane.
[No authors listed] [No authors listed] 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2018 Dec 3. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999992 Free Books & Documents. Review.
No information is available on the use of exemestane during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy. The manufacturer recommends that breastfeeding be discontinued during exemestane therapy …
No information is available on the use of exemestane during breastfeeding. Most sources consider breastfeeding to be contraindicated …
Exemestane.
[No authors listed] [No authors listed] 2017 Jul 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Jul 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644232 Free Books & Documents. Review.
Exemestane is a steroidal inhibitor of aromatase which effectively blocks estrogen synthesis in postmenopausal women and is used as therapy of estrogen receptor positive breast cancer, usually after resection and after failure of tamoxifen. Exemestane has been assoc …
Exemestane is a steroidal inhibitor of aromatase which effectively blocks estrogen synthesis in postmenopausal women and is used as t …
Exemestane.
Scott LJ, Wiseman LR. Scott LJ, et al. Drugs. 1999 Oct;58(4):675-80; discussion 681-2. doi: 10.2165/00003495-199958040-00007. Drugs. 1999. PMID: 10551437 Review.
Exemestane is a steroidal agent which causes inactivation of the aromatase enzyme by binding irreversibly to the substrate binding site. ...Results from a phase III trial indicate that exemestane achieves a similar objective response rate to megestrol as a second-li …
Exemestane is a steroidal agent which causes inactivation of the aromatase enzyme by binding irreversibly to the substrate binding si …
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Yardley DA, et al. Adv Ther. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Epub 2013 Oct 25. Adv Ther. 2013. PMID: 24158787 Free PMC article. Clinical Trial.
Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly prolonged progression-free survival (PFS) versus placebo plus exemestane alone in this patient population. METHODS: BOLERO-2 is a phase …
Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data demonstrated that everolimus and exemestane significantly pro …
Role of Exemestane in the Treatment of Estrogen-Receptor-Positive Breast Cancer: A Narrative Review of Recent Evidence.
Wang Y, Jing F, Wang H. Wang Y, et al. Adv Ther. 2022 Feb;39(2):862-891. doi: 10.1007/s12325-021-01924-2. Epub 2022 Jan 6. Adv Ther. 2022. PMID: 34989983 Review.
RESULTS: The efficacy of exemestane in different treatment settings has been established by numerous clinical studies. Exemestane is recommended as an adjuvant treatment in postmenopausal women previously treated with tamoxifen in trials comparing 5 years of tamoxif …
RESULTS: The efficacy of exemestane in different treatment settings has been established by numerous clinical studies. Exemestane …
Unravelling exemestane: From biology to clinical prospects.
Sobral AF, Amaral C, Correia-da-Silva G, Teixeira N. Sobral AF, et al. J Steroid Biochem Mol Biol. 2016 Oct;163:1-11. doi: 10.1016/j.jsbmb.2016.03.019. Epub 2016 Mar 15. J Steroid Biochem Mol Biol. 2016. PMID: 26992705 Review.
AIs block estrogens biosynthesis by inhibiting the enzyme aromatase, preventing tumor progression. Exemestane, a third-generation steroidal AI, belongs to this class of drugs and is currently used in clinic to treat postmenopausal women, due to its high efficacy and good t …
AIs block estrogens biosynthesis by inhibiting the enzyme aromatase, preventing tumor progression. Exemestane, a third-generation ste …
Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED, Scott LJ. Deeks ED, et al. Drugs. 2009;69(7):889-918. doi: 10.2165/00003495-200969070-00007. Drugs. 2009. PMID: 19441873 Review.
Exemestane is effective for the treatment of postmenopausal women with early-stage or advanced breast cancer. ...Moreover, preliminary data suggest that the efficacy of exemestane is generally no different to that of tamoxifen in the primary adjuvant treatment of ea …
Exemestane is effective for the treatment of postmenopausal women with early-stage or advanced breast cancer. ...Moreover, preliminar …
Exemestane: a milestone against breast cancer.
Shetty YC, Chakkarwar PN, Acharya SS, Rajadhyaksha VD. Shetty YC, et al. J Postgrad Med. 2007 Apr-Jun;53(2):135-8. doi: 10.4103/0022-3859.32218. J Postgrad Med. 2007. PMID: 17495383 Review.
It has also been evaluated for its safety profile, especially on bone and lipids. Exemestane provides hope to the patients with breast cancer both in early and metastatic disease. This review analyzes all the aspects of exemestane therapy....
It has also been evaluated for its safety profile, especially on bone and lipids. Exemestane provides hope to the patients with breas …
Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
di Salle E, Ornati G, Giudici D, Lassus M, Evans TR, Coombes RC. di Salle E, et al. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):137-43. doi: 10.1016/0960-0760(92)90198-r. J Steroid Biochem Mol Biol. 1992. PMID: 1525055 Review.
Exemestane (FCE 24304; 6-methylenandrosta-1,4-diene-3,17-dione) is a novel orally active irreversible aromatase inhibitor. ...No effects on plasma levels of cortisol, aldosterone, 17-hydroxyprogesterone, DHEAS, LH and FSH, and no significant adverse events were observed up …
Exemestane (FCE 24304; 6-methylenandrosta-1,4-diene-3,17-dione) is a novel orally active irreversible aromatase inhibitor. ...No effe …
Clinical utility of exemestane in the treatment of breast cancer.
Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F. Zucchini G, et al. Int J Womens Health. 2015 May 27;7:551-63. doi: 10.2147/IJWH.S69475. eCollection 2015. Int J Womens Health. 2015. PMID: 26064072 Free PMC article. Review.
Exemestane is a steroidal third-generation AI now used in all treatment settings for breast cancer. ...In conclusion, exemestane can be considered an effective and well-tolerated endocrine treatment option for all stages of breast cancer....
Exemestane is a steroidal third-generation AI now used in all treatment settings for breast cancer. ...In conclusion, exemestane …
1,736 results